FDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026)

On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. On Kalshi, the roflumilast approval decision is priced as a binary contract reflecting the probability of FDA approval by the June 2026 resolution date. Traders buy or sell shares corresponding to yes or no outcomes, with contract value ranging from zero to one dollar. The current market price reflects the collective assessment of approval likelihood. Kalshi's order-matching engine aggregates buy and sell interest, and spreads tighten as volume increases. Price discovery accelerates when regulatory milestones occur, such as FDA meeting announcements or clinical data releases relevant to Arcutis's submission.

The market resolves on Jul 1, 2026, capturing the FDA's decision on roflumilast (ARQ-151) for Arcutis Biotherapeutics. Resolution hinges on whether the agency issues an approval or denial by that date. Traders should monitor the FDA's Prescription Drug User Fee Act (PDUFA) target action date, advisory committee meetings, and any regulatory communications that signal the likely outcome. Early termination, complete response letters, or approval announcements will trigger market settlement. Delays beyond the resolution window may result in contract expiration without resolution if no definitive FDA decision has been issued.

Key catalysts include clinical trial updates, FDA meeting announcements, and advisory committee recommendations. Positive efficacy or safety data from ongoing studies would likely boost approval odds, while safety signals or efficacy shortfalls could trigger sharp declines. Regulatory guidance letters, complete response letters, or requests for additional information shift market sentiment materially. Competitive approvals in the same indication may influence perceived regulatory appetite. Company earnings calls, investor presentations, and management commentary on regulatory interactions provide real-time signals. Finally, FDA staffing changes, policy shifts, or precedent-setting decisions in related therapeutic areas can reshape market expectations for roflumilast's pathway.